Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 719 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Biliary Tract Clear all

Conditions: Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer, Gastric Cancer, Colorectal Cancer, Glioblastoma, Biliary Tract Cancers, Pancreatic Cancer
Interventions: Pembrolizumab, Lenvatinib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 611 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 14
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 11 more

Conditions: Primary Sclerosing Cholangitis, Trisomy 7, Cholangiocarcinoma, Chemoprevention
Interventions: Erlotinib (Tarceva); Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma
Interventions: tucatinib, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 21
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 10 more

Conditions: Biliary Cancer
Interventions: SPI-1620, Docetaxel; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 6
States / cities: Miami, Florida • Tampa, Florida • St Louis, Missouri + 3 more

Conditions: Recurrent or Metastatic Solid Tumors
Interventions: Ifinatamab deruxtecan; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 18
States / cities: Los Angeles, California • Whittier, California • Skokie, Illinois + 13 more

Conditions: Primary Biliary Cholangitis
Interventions: APD334; Drug
Lead sponsor: Arena Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 4
States / cities: Sacramento, California • Houston, Texas • San Antonio, Texas + 1 more

Conditions: CHOLELITHIASIS
Interventions: Single-port cholecystectomy, Four-port laparoscopic cholecystectomy; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cholangiocarcinoma, Klatskin Tumor, Biliary Tract Cancer
Interventions: External beam radiation and Cyberknife radiosurgery boost and capecitabine; Radiation
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Bile Duct Cancer, Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma of the Extrahepatic Bile Duct
Interventions: Cabozantinib; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Inflammatory Bowel Disease (IBD), Primary Sclerosing Cholangitis (PSC), Colorectal Neoplasms, Colorectal Cancer
Interventions: Not listed
Lead sponsor: Exact Sciences Corporation; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 24
States / cities: Phoenix, Arizona • La Jolla, California • Miami, Florida + 18 more

Conditions: Cholestasis
Interventions: Omegaven; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: Up to 18 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: San Diego, California

Conditions: Adult Primary Cholangiocellular Carcinoma, Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions: erlotinib hydrochloride, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Autoimmune Liver Disease, Primary Sclerosing Cholangitis, Autoimmune Hepatitis
Interventions: Not listed
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Years to 23 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2030
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Primary Biliary Cholangitis
Interventions: Saroglitazar Magnesium 1 mg; Drug
Lead sponsor: Zydus Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 17
States / cities: Los Angeles, California • Pasadena, California • Sacramento, California + 14 more

Conditions: Cholestasis, Cholestasis of Parenteral Nutrition
Interventions: Omegaven; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 14 Days to 5 Years
Enrollment: 293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Gallbladder Disease
Interventions: SILS™ port laparoscopic cholecystectomy, Four Port Laparoscopic Cholecystectomy; Procedure
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 8
States / cities: New Haven, Connecticut • Tampa, Florida • Chicago, Illinois + 5 more

Conditions: Cholelithiasis, Biliary Dyskinesia
Interventions: NOTES Transvaginal Cholecystectomy; Procedure
Lead sponsor: Baystate Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Springfield, Massachusetts

Conditions: Thymoma, Stomach Neoplasms, Pancreatic Neoplasms, Mesothelioma, Biliary Tract Neoplasms, Mesothelin Expressing Neoplasms
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years to 100 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pancreatic Neoplasms, Biliary Tract Neoplasms, Pancreatitis, Chronic, Duodenal Neoplasms
Interventions: pancreaticojejunostomy; Procedure
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Biliary Atresia, Kasai, Cholestasis in Newborn, Cholestasis in Newborn Infant
Interventions: Indocyanine Green; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 2 Weeks to 4 Months
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Liver Cirrhosis, Biliary
Interventions: Methotrexate; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 20 Years to 69 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2004
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • New Haven, Connecticut + 9 more

Conditions: Colitis, Ulcerative, Cholangitis, Sclerosing
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cancer
Interventions: capecitabine, irinotecan hydrochloride; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Periampullary Tumor, Common Bile Duct Neoplasms, Duodenal Neoplasms
Interventions: Preoperative hyperbaric oxygen; Drug
Lead sponsor: Florida Hospital Tampa Bay Division; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Tampa, Florida

Search by objective public record fields.

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC)

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis

A Comparison of Single Port and Four Port Laparoscopic Gallbladder Removal

Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor)

Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma

Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease

Use of Omega 3 Oil Emulsion for Parenteral Nutrition Associated Cholestasis

Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer

MRI Based Biomarkers in Pediatric Autoimmune Liver Disease

Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis

Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants

SILS™ Port Laparoscopic Cholecystectomy Post Market Study

Natural Orifice Translumenal Endoscopic Surgery (NOTES) Transvaginal Cholecystectomy

Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

A Randomized Trial of Two Surgical Techniques for Pancreaticojejunostomy in Patients Undergoing Pancreaticoduodenectomy

The Use of Near-Infrared Fluorescence Cholangiography With Indocyanine Green (ICG) in the Work Up of Neonatal Cholestasis

Ursodiol-Methotrexate for Primary Biliary Cirrhosis

Compare Conventional Colonosocpy to Endoscopic AFI, NBI for Dysplasia Detection for Ulcerative Colitis & Cholangitis

Irinotecan and Capecitabine in Treating Patients With Solid Tumors

Pancreaticoduodenectomy With or Without Preoperative Hyperbaric Oxygen Therapy